For further guidance, please refer to our peptide reconstitution page
GLP-3: Often considered a misnomer or a theoretical fragment in older literature
10.3389/fnmol.2024.1388759 92 GuoM.CaoQ.XiaS.CaoX.ChenJ.QianY.et al (2023)
the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use
Its benefits on CVD in the form of weight reduction 2-4 kg versus placebo and 4.8 kg versus insulin treated patients
Its definitely something that we should be made aware of, says Alexandra Sowa, MD, who specializes in these medications